<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33380/2305-2066-2019-8-2-74-79</article-id><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-684</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАЦЕВТИЧЕСКАЯ ТЕХНОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACEUTICAL TECHNOLOGY</subject></subj-group></article-categories><title-group><article-title>Разработка состава и технологии получения гранул омепразола в аппарате псевдоожиженного слоя</article-title><trans-title-group xml:lang="en"><trans-title>Research and Development of the Composition and Technology Receving of Granules of Omeprazol in the Fluid Bed Apparatus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мазова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Mazova</surname><given-names>N. V.</given-names></name></name-alternatives><email xlink:type="simple">natalia.mironcheva@pharminnotech.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Марченко</surname><given-names>А. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Marchenko</surname><given-names>A. L.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смехова</surname><given-names>И. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Smehova</surname><given-names>I. E.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Санкт-Петербургский государственный химико-фармацевтический университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint-Petersburg State Chemical and Pharmaceutical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>29</day><month>05</month><year>2019</year></pub-date><volume>8</volume><issue>2</issue><fpage>74</fpage><lpage>79</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мазова Н.В., Марченко А.Л., Смехова И.Е., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Мазова Н.В., Марченко А.Л., Смехова И.Е.</copyright-holder><copyright-holder xml:lang="en">Mazova N.V., Marchenko A.L., Smehova I.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/684">https://www.pharmjournal.ru/jour/article/view/684</self-uri><abstract><sec><title>Введение</title><p>Введение. Исследование посвящено вопросам разработки состава и технологии гранул омепразола. Установлено, что самой оптимальной лекарственной формой для препаратов ингибиторов протонной помпы считается таблетка с системой множества пеллет (микрочастиц). В случае производства данных препаратов в микрогранулах частицы покрыты несколькими защитными оболочками. Для разработки микрогранул омепразола предложена технология наслаивания в аппарате псевдоожиженного слоя.</p></sec><sec><title>Цель</title><p>Цель. Получение в аппарате псевдоожиженного слоя покрытых кишечнорастворимой оболочкой микрогранул омепразола.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Для решения поставленной цели определены технологические характеристики полученных при различных режимах работы аппарата псевдоожиженного слоя гранулятов омепразола, такие как форма гранул, фракционный состав и насыпная плотность методами, описанными Государственной фармакопеей XIII издания.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. В результате исследования обоснован выбор полимеров для послойного нанесения в процессе гранулирования субстанции омепразола. Произведен подбор кишечнорастворимого полимера различных фирм производителей для обеспечения необходимого профиля высвобождения омепразола в организме человека. Выбран сополимер метакриловой кислоты – Kollicoat MAE 100 P. Особое внимание уделено получению кишечнорастворимых гранул омепразола правильной сферообразной формы с минимальной шероховатостью и улучшенной сыпучестью для дальнейшего таблетирования. С целью получения гранул омепразола сферообразной формы произведен подбор оптимального режима работы аппарата псевдоожиженного слоя для осуществления процесса нанесения кишечнорастворимого полимера. По итогам экспериментов определена зависимость качества фракционного состава и внешнего вида гранул омепразола от температуры, давления и скорости подачи полимера. Кроме того, установлено, что равномерность нанесения и толщина слоя нанесенного кишечнорастворимого полимера на гранулы омепразола зависят не только от скорости подачи полимера, но и от размера капель подаваемого раствора.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. In this research is devoted to questions of development of structure and technology of granules of an omeprazole. It is established that the most optimal dosage form for medicines of inhibitors of a proton pump is considered to be the tablet with a multiple-unit pellets system (microparticles). In this case of the production of these medicines in the microgranules of a particle are covered with several protective covers. For development of microgranules of an omeprazole is offered the technology of lamination in the fluid bed apparatus.</p></sec><sec><title>Aim</title><p>Aim. To receive in the fluid bed apparatus of the microgranules of an omeprazole covered with the enteric cover.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. To solve this problem technical characteristics on the granulates of an omeprazole received at various operating modes of the fluid bed apparatus are defined such as form of granules, fractional structure and bulk density are determined by the methods described by the State Pharmacopeia of the XIII edition.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. As a result of a research the choice of polymers for layered deposition in the granulation process of a substance of omeprazole is substantiated. Produced selection of enteric polymer of various firms of producers is made for providing a necessary profile of release of an omeprazole in a human body. A copolymer of methacrylic acid – Kollicoat MAE 100 P is chosen. Special attention is paid to receiving the enteric granules of an omeprazole of the correct spherical form with minimum roughness and the improved flowability for further tabletting. For the purpose of receiving granules of an omeprazole of a spherical form selection of an optimum operating mode of the device of a fluid bed apparatus is made for implementation of process of applying the enteric polymer. Following the results of experiments the dependence of quality of fractional structure and appearance of granules of an omeprazole on temperature, pressure and feed rate of polymer is defined. Besides, it is established that the uniformity of application and thickness of a layer of the applied enteric polymer on granules of an omeprazole depend not only on the polymer feed rate, but also on the size of drops of the feed solution.</p></sec><sec><title>Conclusion</title><p>Conclusion. It is established that the quality of the granules of an omeprazole received the enteric polymer was affected by such factors of technological parameters of the fluid bed apparatus as: temperature of the entering air in the apparatus, the air pressure upon a nozzle, air pressure upon a gas-distributing grid of the apparatus, speed of the given polymer, a lot of loading of granules, air temperature of a layer of granules, duration of drying of granules upon termination of process of application of the enteric polymer.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ингибиторы протонной помпы</kwd><kwd>грануляция</kwd><kwd>аппарат псевдоожиженного слоя</kwd><kwd>кишечнорастворимые полимеры</kwd></kwd-group><kwd-group xml:lang="en"><kwd>inhibitors of proton pomp</kwd><kwd>granulation</kwd><kwd>fluid bed apparatus</kwd><kwd>enteric polymer</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Маев И. В., Вьючнова Е. С., Щекина М. И. Гастроэзофагеальная рефлюксная болезнь – болезнь XXI века. Лечащий Врач. 2004; 4: 10–14.</mixed-citation><mixed-citation xml:lang="en">Maev I. V., Vuchnova E. S., Scekina M. I. Gastroesophageal reflux disease is a disease of the XXI century. LechashchiyVrach – Attending doctor. 2004; 4: 10–14 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Warrington S., Baisley K., Dunn K., Boyce M., Morocutti A. Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects. European Journal of Clinical Pharmacology. 2006; 62: 685–691. https://doi.org/10.1007/s00228-006-0148-5.</mixed-citation><mixed-citation xml:lang="en">Warrington S., Baisley K., Dunn K., Boyce M., Morocutti A. Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects. European Journal of Clinical Pharmacology.2006; 62: 685–691.DOI: 10.1007/s00228-006-0148-5.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Платошкин Э. Н. Ингибиторы протонной помпы – эталон лечения кислотозависимых заболеваний. Медицинские новости. 2007; 10: 25–30.</mixed-citation><mixed-citation xml:lang="en">Platoshkin E. N.Inhibitors of a proton pomp – standard of treatment of acid-related diseases. Medicinskienovosti – Medical news. 2007; 10: 25–30 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Dean L. Comparing Proton Pump Inhibitors. Journal of Pharmaceutical Sciences. 2010; 19(6): 417.</mixed-citation><mixed-citation xml:lang="en">Dean L. Comparing Proton Pump Inhibitors. Journal of Pharmaceutical Sciences. 2010; 19(6): 417.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Могилюк В. В. Пероральные кишечнорастворимые лекарственные формы. Провизор. 2009; 6: 45–51.</mixed-citation><mixed-citation xml:lang="en">Mogiluk V. V. Oralentericdosageforms. Provisor – Pharmacist. 2009; 6: 45–51 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Могилюк В. В. Мультипартикулярные таблетки. Фармацевтическая отрасль. 2014; 2 (43): 36–39.</mixed-citation><mixed-citation xml:lang="en">Mogiluk V. V. Multiparticaltablets. FarmacevticheskaiaOtrasal – Pharmaceutical industry. 2014; 2 (43): 36–39 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Леонова М. В. Белоусов Ю. Б. Лекарственные формы с модифицированным высвобождением и системы доставки. М.: Литтера. 2011; 656.</mixed-citation><mixed-citation xml:lang="en">Leonova M. V., Belousov U. B. Modified Release Dosage Forms and Delivery System. Мoscow: Littera. 2011: 656 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Padhee K., Chowdhary K. A., Pattnaik S. N., Sahoo S. K., Pathak N. Design and development of Multiple-Unit. Extended release drug delivery system of Verapamil HCL by Pelletization Technique. Int. J. Drug Dev. &amp; Res. 2011; 3(3): 118–125.</mixed-citation><mixed-citation xml:lang="en">Padhee K., Chowdhary K. A., Pattnaik S. N., Sahoo S. K., Pathak N. Design and development of Multiple-Unit, Extended release drug delivery system of Verapamil HCL by Pelletization Technique. Int. J. Drug Dev. &amp; Res. 2011; 3(3): 118–125.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
